XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

Abstract Background Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity and restoring inhibition of AKT by everolimus. This study evaluated the addition of xentuzumab to everolimus and exemestane in patients with advanced breast canc...

Full description

Bibliographic Details
Main Authors: Peter Schmid, Javier Cortes, Ana Joaquim, Noelia Martínez Jañez, Serafín Morales, Tamara Díaz-Redondo, Sibel Blau, Patrick Neven, Julie Lemieux, José Ángel García-Sáenz, Lowell Hart, Tsvetan Biyukov, Navid Baktash, Dan Massey, Howard A. Burris, Hope S. Rugo
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Breast Cancer Research
Subjects:
Advanced breast cancer
HR+/HER2−
Non-visceral disease
Xentuzumab
Insulin-like growth factor
Everolimus
Online Access:https://doi.org/10.1186/s13058-023-01649-w

Internet

https://doi.org/10.1186/s13058-023-01649-w

Similar Items